At a glance
- Originator Procter & Gamble
- Class Osteoporosis therapies; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 12 Dec 2003 No development reported - Preclinical for Osteoporosis in USA (unspecified route)
- 25 Sep 2001 New profile
- 25 Sep 2001 Preclinical development for Osteoporosis in USA (Unknown route)